Remimazolam Besylate — Active Pharmaceutical Ingredient

Remimazolam Besylate is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: POWDER. Routes: INTRAVENOUS.

This content is for informational purposes only. Always consult a healthcare professional.

Remimazolam Besylate (1 brand name, 1 dosage form, 1 route)

Available dosage forms: POWDER.

Routes of administration: INTRAVENOUS.

Brand Names

  • BYFAVO

Indications and Usage

BYFAVO® is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.

Contraindications

BYFAVO is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40 [see Warnings and Precautions (5.3)].

Adverse Reactions

The following serious adverse reactions are discussed in greater detail in other sections: Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)]

Mechanism of Action

BYFAVO is a benzodiazepine. BYFAVO binds to brain benzodiazepine sites (gamma amino butyric acid type A [GABAA] receptors), while its carboxylic acid metabolite (CNS7054) has a 300 times lower affinity for the receptor. BYFAVO, like other benzodiazepines, did not show clear selectivity between subtypes of the GABAA receptor.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.